133 related articles for article (PubMed ID: 9916266)
21. Clinical and genetic analysis of Fabry disease: report of six cases including three heterozygous females.
Nagasaki A; Nishie W; Sato K; Oba I; Noguchi E; Akitsu H; Sawamura D; Shimizu H
J Dermatol Sci; 2008 Oct; 52(1):61-4. PubMed ID: 18555667
[No Abstract] [Full Text] [Related]
22. Absence of cornea verticillata in hemizygotes of a novel mutation in fabry disease.
Huerva V; Martín M; Canto LM; Yagüe J
Cornea; 2008 Sep; 27(8):970-2. PubMed ID: 18724168
[TBL] [Abstract][Full Text] [Related]
23. Mutations of the GLA gene in Korean patients with Fabry disease and frequency of the E66Q allele as a functional variant in Korean newborns.
Lee BH; Heo SH; Kim GH; Park JY; Kim WS; Kang DH; Choe KH; Kim WH; Yang SH; Yoo HW
J Hum Genet; 2010 Aug; 55(8):512-7. PubMed ID: 20505683
[TBL] [Abstract][Full Text] [Related]
24. Fabry disease in a female patient due to a de novo point mutation at position 691 of exon 5.
Brokalaki EI; Hentschke M; Grabbe S; Jansen T
Eur J Med Res; 2006 Jul; 11(7):306-8. PubMed ID: 16899426
[TBL] [Abstract][Full Text] [Related]
25. Pseudodeficiency of alpha-galactosidase A.
Bach G; Rosenmann E; Karni A; Cohen T
Clin Genet; 1982 Jan; 21(1):59-64. PubMed ID: 6279339
[TBL] [Abstract][Full Text] [Related]
26. Megadolichobasilar anomaly with thrombosis in a family with Fabry's disease and a novel mutation in the alpha-galactosidase A gene.
Garzuly F; Maródi L; Erdös M; Grubits J; Varga Z; Gelpi E; Rohonyi B; Mázló M; Molnár A; Budka H
Brain; 2005 Sep; 128(Pt 9):2078-83. PubMed ID: 15947062
[TBL] [Abstract][Full Text] [Related]
27. Fabry disease: twenty-two novel mutations in the alpha-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes.
Ashton-Prolla P; Tong B; Shabbeer J; Astrin KH; Eng CM; Desnick RJ
J Investig Med; 2000 Jul; 48(4):227-35. PubMed ID: 10916280
[TBL] [Abstract][Full Text] [Related]
28. Clinical spectrum of Anderson Fabry disease in a Romanian family.
Tudor A; Muşat A; Doscan A; Bari M; Zapucioiu C; Urdea E; Cochior D; Peţa D
Rom J Intern Med; 2006; 44(2):201-10. PubMed ID: 17236300
[TBL] [Abstract][Full Text] [Related]
29. Fabry disease: detection of 13-bp deletion in alpha-galactosidase A gene and its application to gene diagnosis of heterozygotes.
Ishii S; Sakuraba H; Shimmoto M; Minamikawa-Tachino R; Suzuki T; Suzuki Y
Ann Neurol; 1991 May; 29(5):560-4. PubMed ID: 1650161
[TBL] [Abstract][Full Text] [Related]
30. A successful approach for the detection of Fabry patients in Argentina.
Rozenfeld PA; Tarabuso A; Ebner R; Ramallo G; Fossati CA
Clin Genet; 2006 Apr; 69(4):344-8. PubMed ID: 16630168
[TBL] [Abstract][Full Text] [Related]
31. A novel alpha-galactosidase a mutant (M42L) identified in a renal variant of Fabry disease.
Rosenthal D; Lien YH; Lager D; Lai LW; Shang S; Leung N; Fervenza FC
Am J Kidney Dis; 2004 Nov; 44(5):e85-9. PubMed ID: 15492942
[TBL] [Abstract][Full Text] [Related]
32. An association study of inflammatory cytokine gene polymorphisms in Fabry disease.
Safyan R; Whybra C; Beck M; Elstein D; Altarescu G
Eur Cytokine Netw; 2006 Dec; 17(4):271-5. PubMed ID: 17353161
[TBL] [Abstract][Full Text] [Related]
33. A family with Fabry disease diagnosed by a single angiokeratoma.
Corry A; Feighery C; Alderdice D; Stewart F; Walsh M; Dolan OM
Dermatol Online J; 2011 Apr; 17(4):5. PubMed ID: 21549080
[TBL] [Abstract][Full Text] [Related]
34. Middelheim Fabry Study (MiFaS): a retrospective Belgian study on the prevalence of Fabry disease in young patients with cryptogenic stroke.
Brouns R; Sheorajpanday R; Braxel E; Eyskens F; Baker R; Hughes D; Mehta A; Timmerman T; Vincent MF; De Deyn PP
Clin Neurol Neurosurg; 2007 Jul; 109(6):479-84. PubMed ID: 17509753
[TBL] [Abstract][Full Text] [Related]
35. The molecular defect leading to Fabry disease: structure of human alpha-galactosidase.
Garman SC; Garboczi DN
J Mol Biol; 2004 Mar; 337(2):319-35. PubMed ID: 15003450
[TBL] [Abstract][Full Text] [Related]
36. [Substrate specificity of multiple forms of human alpha-D-galactosidase and alpha-D-fucosidase].
Baskaeva EM; Shono NI; Kozlova IK; Vidershaĭn GIa
Biokhimiia; 1989 Mar; 54(3):421-6. PubMed ID: 2546612
[TBL] [Abstract][Full Text] [Related]
37. Angiokeratoma corporis diffusum with glycopeptiduria due to deficient lysosomal alpha-N-acetylgalactosaminidase activity. Clinical, morphologic, and biochemical studies.
Kanzaki T; Yokota M; Irie F; Hirabayashi Y; Wang AM; Desnick RJ
Arch Dermatol; 1993 Apr; 129(4):460-5. PubMed ID: 8466216
[TBL] [Abstract][Full Text] [Related]
38. Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele.
Yasuda M; Shabbeer J; Benson SD; Maire I; Burnett RM; Desnick RJ
Hum Mutat; 2003 Dec; 22(6):486-92. PubMed ID: 14635108
[TBL] [Abstract][Full Text] [Related]
39. Neurological manifestations of Fabry disease in female carriers.
Bird TD; Lagunoff D
Ann Neurol; 1978 Dec; 4(6):537-40. PubMed ID: 217299
[TBL] [Abstract][Full Text] [Related]
40. Properties of multiple molecular forms of alpha-galactosidase and alpha-N-acetylgalactosaminidase from normal and Fabry leukocytes.
Salvayre R; Maret A; Negre A; Douste-Blazy L
Eur J Biochem; 1979 Oct; 100(2):377-83. PubMed ID: 41709
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]